Hydrogen sulfide blocks HIV rebound by maintaining mitochondrial bioenergetics and redox homeostasis
Abstract
A fundamental challenge in human immunodeficiency virus (HIV) eradication is to understand how the virus establishes latency, maintains stable cellular reservoirs, and promotes rebound upon interruption of antiretroviral therapy (ART). Here, we discovered an unexpected role of the ubiquitous gasotransmitter hydrogen sulfide (H2S) in HIV latency and reactivation. We show that reactivation of HIV is associated with downregulation of the key H2S producing enzyme cystathionine-γ-lyase (CTH) and reduction in endogenous H2S. Genetic silencing of CTH disrupts redox homeostasis, impairs mitochondrial function, and remodels the transcriptome of latent cells to trigger HIV reactivation. Chemical complementation of CTH activity using a slow-releasing H2S donor, GYY4137, suppressed HIV reactivation and diminished virus replication. Mechanistically, GYY4137 blocked HIV reactivation by inducing the Keap1-Nrf2 pathway, inhibiting NF-κB, and recruiting the epigenetic silencer, YY1, to the HIV promoter. In latently infected CD4+ T cells from ART-suppressed human subjects, GYY4137 in combination with ART prevented viral rebound and improved mitochondrial bioenergetics. Moreover, prolonged exposure to GYY4137 exhibited no adverse influence on proviral content or CD4+ T cell subsets, indicating that diminished viral rebound is due to a loss of transcription rather than a selective loss of infected cells. In summary, this work provides mechanistic insight into H2S-mediated suppression of viral rebound and suggests exploration of H2S donors to maintain HIV in a latent form.
Editor's evaluation
Pal and colleagues show that hydrogen sulfide (H2S) inhibits HIV replication and reactivation by a variety of mechanisms including inhibition of NF-κB and recruitment of the epigenetic silencer, YY1, to the HIV promoter. They further report that H2S helps in maintaining mitochondrial bioenergetics and redox homeostasis. Altogether, the study provides novel insights into the mechanisms underlying HIV transcription and reactivation.
https://doi.org/10.7554/eLife.68487.sa0Introduction
Human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS), is responsible for 0.6 million deaths and 1.7 million new infections in 2019 (https://www.who.int/data/gho/data/themes/hiv-aids). Despite advances in antiretroviral therapy (ART), the persistence of latent but replication-competent HIV in cellular reservoirs is a major barrier to cure (Finzi et al., 1997; Sengupta and Siliciano, 2018; Cohn et al., 2020). Understanding host factors and signaling pathways underlying HIV latency and rebound upon cessation of ART is of the highest importance in the search for an HIV cure (Deeks et al., 2016; Collins et al., 2020). Host-generated gaseous signaling molecules such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) modulate antimicrobial activity, inflammatory response, and metabolism of immune cells to influence bacterial and viral infections (Chinta et al., 2016; Pal et al., 2018; Tinajero-Trejo et al., 2013; Rahman et al., 2020; Shiloh et al., 2008; Braverman and Stanley, 2017). Surprisingly, while circumstantial evidence links NO and CO with HIV-1 infection (Blond et al., 2000; Devadas and Dhawan, 2006; Liu et al., 2016), the role of H2S remained completely unexplored.
H2S is primarily synthesized in mammals, including humans, via the reverse transsulfuration pathway using methionine and cysteine metabolizing enzymes cystathionine-gamma-lyase (CSE/CTH), cystathionine-beta-synthase (CBS), and cysteine-aminotransferase (CAT)–3-mercaptopyruvate sulfurtransferase (MPST), respectively (Pal et al., 2018). Because H2S is lipophilic, it rapidly permeates through biological membranes without membrane channels (lipid bilayer permeability, PM≥0.5±0.4 cm/s), dissociates into HS– and S2– in aqueous solution, and maintains an HS–:H2S ratio of 3:1 at physiological pH (Pal et al., 2018). Interestingly, expression and enzymatic activity of CTH was diminished in human CD8+ T cells and hepatic tissues derived from AIDS patients, respectively (Hyrcza et al., 2007; Martin et al., 2001). Additionally, the levels of H2S precursors L-cysteine and methionine were severely limited in AIDS patients (Hortin et al., 1994). Also, HIV infection reduces the major cellular antioxidant glutathione (GSH) (Staal et al., 1992), whose production is dependent on L-cysteine and H2S (Kimura et al., 2010; McBean, 2012). Consequently, supplementation with N-acetyl cysteine (NAC), which is an exogenous source of L-cysteine, has been proposed for AIDS treatment (Roederer et al., 1993). Since functional CBS and CTH enzymes are known to promote T cell activation and proliferation (Miller et al., 2012), endogenous levels of H2S can potentiate T cell-based immunity against HIV. Therefore, we think that the endogenous levels and biochemical activity of H2S, which critically depends upon the cysteine and transsulfuration pathway (Mathai et al., 2009), are likely to be important determinants of HIV infection.
Calibrated production of H2S improves the functioning of various immune cells by protecting them from deleterious oxidants, stimulating mitochondrial oxidative phosphorylation (OXPHOS), and counteracting systemic inflammation (Pal et al., 2018; Modis et al., 2014; Fu et al., 2012). In contrast, supraphysiological concentrations of H2S exert cytotoxicity by inhibiting OXPHOS, promoting inflammation, and inducing redox imbalance (Pal et al., 2018; Modis et al., 2014; Fu et al., 2012). These H2S-specific physiological changes are also crucial for HIV-1 infection. First, chronic inflammation contributes to HIV-1 pathogenesis by affecting innate and adaptive immune responses (Deeks et al., 2013), impairing recovery of CD4+ T cells post-ART (Nakanjako et al., 2011), increasing the risk of comorbidities (Leng and Margolick, 2015; Alzahrani et al., 2019), and worsening organ function (Tattevin et al., 2007). Second, HIV-1 preferentially infects CD4+ T cells with high OXPHOS (Valle-Casuso et al., 2019), relies on glycolysis for continuous replication (Hegedus et al., 2014), and reactivates in response to altered mitochondrial bioenergetics (Tyagi et al., 2020). Third, a higher capacity to resist oxidative stress promotes virus latency, whereas increased oxidative stress levels induce reactivation (Bhaskar et al., 2015; Savarino et al., 2009; Shytaj et al., 2020). Fourth, H2S directly (via S-linked sulfhydration) or indirectly modulates the activity of transcription factors NF-κB and AP-1 (Sen et al., 2012; Xie et al., 2016) that are well known to trigger HIV-1 reactivation from latency (Williams et al., 2007; Brooks et al., 2003; Duverger et al., 2013). Finally, the thioredoxin/thioredoxin reductase (Trx/TrxR) system crucial for maintaining HIV-1 reservoirs (Chirullo et al., 2013) has been shown to regulate H2S-mediated S-persulfidation (Dóka et al., 2016). Altogether, many physiological processes vital for HIV-1 pathogenesis overlap with the underlying mechanism of H2S-mediated signaling.
Based on the role of H2S in regulating redox balance, mitochondrial bioenergetics, and inflammation, we hypothesize that intracellular levels of H2S modulate the HIV-1 latency and reactivation program. To test this hypothesis, we utilized cell line-based models of HIV-1 latency and CD4+ T cells of HIV-1 infected patients on suppressive ART, which harbors the latent but replication-competent virus. Biochemical and genetic approaches were exploited to investigate the link between H2S and HIV-1 latency. Finally, we used NanoString gene expression technology, oxidant-specific fluorescent dyes, and real-time extracellular flux analysis to examine the role of H2S in mediating HIV-1 persistence by regulating gene expression, redox signaling, and mitochondrial bioenergetics.
Results
Diminished biogenesis of endogenous H2S during HIV-1 reactivation
To investigate the link between HIV-1 latency and H2S, we measured changes in the expression of genes encoding H2S-generating enzymes CBS, CTH, and MPST in monocytic (U1) and lymphocytic (J1.1 and J-Lat) models of HIV-1 latency (Figure 1A). The U1 and J1.1/J-Lat cell lines are well-studied models of post-integration latency and were derived from chronically infected clones of a promonocytic (U937) and a T-lymphoid (Jurkat) cell line, respectively (Folks et al., 1987; Perez et al., 1991; Jordan et al., 2003). Both U1 and J1.1/J-Lat show very low basal expression of the HIV-1 genome, which can be induced by several latency reversal agents (LRAs) such as PMA, TNF-α, and prostratin (Figure 1B; Folks et al., 1987; Perez et al., 1991; Jordan et al., 2003). First, we confirmed virus reactivation by measuring HIV-1 gag transcript in U1 with a low concentration of PMA (5 ng/ml). Treatment of PMA induces detectable expression of gag at 12 hr, which continued to increase for the entire 36 hr duration of the experiment (Figure 1C). Next, we assessed the mRNA and protein levels of CBS, CTH, and MPST in U1 during virus latency (untreated) and reactivation (PMA-treated). The mRNA and protein expression levels of CTH showed a significant reduction at 24 and 36 hr post-PMA treatment as compared to the untreated control, whereas the expression of CBS was not detected and MPST remained unaffected (Figure 1D–E). As an uninfected control, we measured the expression of CBS, CTH, and MPST in U937 cells. In contrast to U1, PMA treatment stimulated the mRNA and protein levels of CTH in U937 (Figure 1F–G), while CBS was barely detectable. Also, we directly measured endogenous H2S levels using a fluorescent probe 7-azido-4-methylcoumarin (AzMc) that quantitatively detects H2S in living cells (Chen et al., 2013). Consistent with the expression data, reactivation of HIV-1 by PMA reduced H2S generation in U1, whereas H2S levels were significantly increased by PMA in the uninfected U937 (Figure 1H–I).
-
Figure 1—source data 1
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig1-data1-v3.zip
-
Figure 1—source data 2
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig1-data2-v3.zip
-
Figure 1—source data 3
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig1-data3-v3.xlsx
Similar to U1 monocytic cells, PMA treatment reactivated HIV-1 and reduced the expression of CTH in J1.1 lymphocytic cells but not in the uninfected Jurkat cells in a time-dependent manner (Figure 1—figure supplement 1A-B). The expression of CBS was reduced in both J1.1 and Jurkat upon PMA treatment, indicating that only CTH specifically downregulates in response to HIV-1 reactivation (Figure 1—figure supplement 1A-B). In J-Lat cells, HIV-1 genome encodes GFP, which facilitates precise measurement of PMA-mediated HIV-1 reactivation from latency by flow cytometry. Treatment with PMA reactivated HIV-1 in a time-dependent manner and diminished the expression of CBS, CTH, and MPST in J-Lat as compared to Jurkat cells (Figure 1—figure supplement 1C-D). Taken together, these data indicate that HIV-1 reactivation is associated with diminished biogenesis of endogenous H2S.
CTH-mediated reactivation of HIV-1 from latency
Our results suggest that H2S biogenesis via CTH is associated with HIV-1 latency. Therefore, we next asked whether CTH-derived H2S regulates the reactivation of HIV-1 from latency. To test this idea, we depleted endogenous CTH levels in U1 using RNA interference (RNAi). The short hairpin RNA specific for CTH (U1-shCTH) silenced the expression of CTH mRNA and protein by 90% as compared to non-targeting shRNA (U1-shNT) (Figure 2A–B and Supplementary file 1a). Moreover, using AzMC probe, we confirmed the reduction in endogenous H2S levels in U1-shCTH as compared to U1-shNT (Figure 2—figure supplement 1A-B). In addition to H2S production, CTH catalyzes the last step in the reverse transsulfuration pathway to generate cysteine. However, levels of cysteine remain comparable in U1-shCTH and U1-shNT (Figure 2—figure supplement 1C), indicating that other routes for cysteine biosynthesis (e.g., de novo and assimilatory pathways) compensate for CTH depletion in U1. Next, we investigated the effect of H2S depletion via CTH suppression on HIV-1 latency by measuring viral transcription (gag transcript), translation (HIV-1 p24 capsid protein), and release (HIV-1 p24 abundance in the cell supernatant). We found that the low basal expression of HIV-1 gag in U1-shCTH was stimulated by 16-fold upon depletion of CTH (p=0.0018) (Figure 2C). Furthermore, while PMA induced expression of gag transcript by 73-fold in U1-shNT, a further enhancement to 200-fold was observed in U1-shCTH (Figure 2C). Consistent with this, levels of p24 capsid protein inside cells or released in the supernatant were significantly elevated in U1-shCTH as compared to U1-shNT with (p=0.028) or without PMA-treatment (p=0.015) (Figure 2D–E). Deprivation of cysteine in the culture medium does not stimulate viral transcription in U1 (Figure 2—figure supplement 1D), indicating that reduction in H2S levels is likely responsible for the reactivation of HIV-1 in U1-shCTH.
-
Figure 2—source data 1
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig2-data1-v3.zip
-
Figure 2—source data 2
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig2-data2-v3.xlsx
-
Figure 2—source data 3
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig2-data3-v3.xlsx
We also depleted CTH levels in J1.1 cells using RNAi and monitored HIV-1 reactivation by assessing intracellular p24 levels under basal conditions. The depletion of CTH triggered HIV-1 reactivation from latency as evident from a sevenfold increase in p24 levels as compared to shNT (Figure 2—figure supplement 1E). A minor increase in p24 levels (3.8-fold) was also apparent upon the depletion of CBS in J1.1 (Figure 2—figure supplement 1E). Finally, and consistent with U1 and J1.1, genetic silencing of CTH using a CTH specific shRNA or chemical inhibition by propargylglycine (PAG) reactivated HIV-1 in J-Lat cells (Figure 2—figure supplement 1F-I). These data indicate that CTH and likely CTH-derived H2S supports latency and impede the reactivation of HIV-1.
Altered expression of genes involved in HIV-1 reactivation upon CTH depletion
The above results indicate that CTH is a target controlling HIV-1 reactivation from latency, prompting us to investigate the mechanism. Several pathways that induce HIV-1 reactivation from latency are also influenced by H2S. These include redox signaling (Banerjee, 2011), NF-κB pathway (Gao et al., 2012), inflammatory response (Bhatia, 2012), and mitochondrial bioenergetics (Szabo et al., 2014). Hence, we conducted a focused expression profiling of 185 human genes intrinsically linked to HIV-1 reactivation using the NanoString nCounter Technology (see Supplementary file 1b for the gene list) to measure absolute amounts of multiple transcripts without reverse transcription. Because depletion of CTH promoted reactivation of the HIV-1 in U1, we compared the expression profile of U1-shCTH with U1-shNT to further understand the link between H2S biogenesis and HIV-1 latency. Examination of 84 genes related to oxidative stress response revealed differential regulation of 22 genes in U1-shCTH compared with U1-shNT (Figure 2F and Supplementary file 1c). Interestingly, more than 90% of genes showing altered expression were downregulated in U1-shCTH. Of these, genes encoding key cellular antioxidant enzymes and buffers such as catalase (CAT), superoxide dismutase (SOD1), peroxiredoxin family, thioredoxin family (TXN, TXNRD1 and TXNRD2), sulfiredoxin (SRXN1), glutathione metabolism (GCLM, GSS, and GSR), and sulfur metabolism (MPST, AHCY, and MAT2A) were significantly less expressed in U1-shCTH as compared to U1-shNT (Figure 2F). Further, while MPST was downregulated upon CTH knock-down, CBS remained undetectable in U1-shCTH and U1-shNT (Figure 2F). Since oxidative stress elicits HIV-1 reactivation (Bhaskar et al., 2015), these findings indicate that HIV-1 reactivation through CTH depletion could be a consequence of an altered redox balance. Further, pathways involved in promoting HIV-1 reactivation, such as NF-κB signaling (Williams et al., 2007) and apoptosis (Khan et al., 2015), were also induced in U1-shCTH as compared to U1-shNT (Figure 2F). Notably, multiple HIV-1 restriction factors are important for viral latency including type I interferon signaling (IRF2 and STAT-1) (Sgarbanti et al., 2002; Nguyen et al., 2018), APOBEC3G (Gillick et al., 2013), CDK9-CCNT1 ( Amini et al., 2002; Budhiraja et al., 2013), SLP-1 (McNeely et al., 1995), and chromatin remodelers (SMARCB1, BANF1, and YY1) (Rafati et al., 2011; Coull et al., 2000) were downregulated in U1-shCTH. HIV-1 proteins are known to target mitochondria to induce mitochondrial depolarization, elevate mitochondrial reactive oxygen species (ROS), and apoptosis for replication (Badley et al., 2003). Several genes involved in sustaining mitochondrial function and membrane potential (e.g., BAX, UCP2, LHPP, and MPV17) were repressed in U1-shCTH (Figure 2F), highlighting a potential association between unrestricted virus replication, mitochondrial dysfunction, and CTH depletion.
Since PMA is known to reactivate HIV-1 (Pardons et al., 2019b), we examined the gene expression in U1-shNT upon reactivation of HIV-1 by PMA. We found that 80% of genes affected by the depletion of CTH were similarly perturbed in response to PMA. Signature of transcripts associated with oxidative stress response, sulfur metabolism, anti-viral factors, and mitochondrial function was comparable in U1-shCTH and PMA-treated U1-shNT (Figure 2F). Based on these similarities, we hypothesized that combining PMA with CTH depletion would have an additive effect on the expression of genes linked to HIV-1 reactivation. Indeed, exposure of U1-shCTH to PMA induced gene expression changes, which surpassed those produced by PMA treatment or CTH-depletion alone (Figure 2F). Notably, significant expression changes in U1-shCTH upon PMA treatment are consistent with our data showing maximal HIV-1 activation under these conditions (see Figure 2C). Overall, these results indicate that CTH contributes to HIV-1 latency by modulating multiple pathways coordinating cellular homeostasis (e.g., redox balance and mitochondrial function) and the anti-viral response.
CTH is required to maintain redox homeostasis and mitochondrial function
Physiological levels of H2S support redox balance and mitochondrial function by maintaining GSH balance (Kimura et al., 2010), protecting against ROS (Kimura et al., 2010), and acting as a substrate for the electron transport chain (ETC) (Modis et al., 2014; Fu et al., 2012). On this basis, we reasoned that the depletion of CTH could contribute to redox imbalance and mitochondrial dysfunction, both of which are known to promote HIV-1 reactivation (Tyagi et al., 2020; Bhaskar et al., 2015; Singh et al., 2021). We first measured total glutathione content (GSH+GSSG) and GSSG concentration in U1-shNT and U1-shCTH using chemical-enzymatic analysis of whole-cell extract (Bhaskar et al., 2015). Whole-cell glutathione content was not significantly different in U1-shNT and U1-shCTH (p=0.2801) (Figure 3A). However, the GSSG concentration was elevated in U1-shCTH resulting in a concomitant decrease in the GSH/GSSG ratio of U1-shCTH as compared to U1-shNT (p=0.0032) (Figure 3A). The increased GSSG pool and reduced GSH/GSSG poise confirm that cells are experiencing oxidative stress upon CTH depletion. We measured total ROS using a fluorescent probe, 5,6-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA), which non-specifically responds to any type of ROS within the cells. Both U1-shNT and U1-shCTH showed comparable levels of cytoplasmic ROS (Figure 3—figure supplement 1A), which remained unchanged after stimulation with PMA. In addition to cytoplasmic ROS, we also measured mitochondrial ROS (mitoROS) using the red fluorescent dye MitoSOX, which selectively stains mitoROS. Lowering the levels of CTH severely increased mitoROS in U1, which was further accentuated after PMA stimulation (Figure 3B). We then studied the effect of CTH depletion on mitochondrial functions using a Seahorse XF Extracellular Flux Analyzer (Agilent) as described previously by us (Figure 3C; Tyagi et al., 2020; Szabo et al., 2014). Both basal and ATP-coupled respiration was significantly decreased in U1-shCTH as compared to U1-shNT (Figure 3D–E), consistent with the role of endogenous H2S in reducing cytochrome C oxidase for respiration (Szabo et al., 2014). The maximal respiratory capacity, attained by the dissipation of the mitochondrial proton gradient with the uncoupler FCCP, was markedly diminished in U1-shCTH (Figure 3E). The maximal respiration also facilitated the estimation of the spare respiratory capacity (SRC), which was nearly exhausted in U1-shCTH. Additional hallmarks of HIV-1 reactivation and dysfunctional mitochondria such as coupling efficiency and non-mitochondrial oxygen consumption rate (nmOCR) (Tyagi et al., 2020) were also adversely affected upon depletion of CTH (Figure 3E). These results indicate that CTH depletion decelerates respiration, diminishes the capacity of macrophages to maximally respire, and promotes nmOCR. All of these parameters are important features of mitochondrial health and are likely to be crucial for maintaining HIV-1 latency.
A small-molecule H2S donor diminished HIV-1 reactivation and viral replication
Having shown that diminished levels of endogenous H2S are associated with redox imbalance, mitochondrial dysfunction, and reactivation of HIV-1 from latency, we next examined if elevating H2S levels using a small-molecule H2S donor- GYY4137 sustains HIV-1 latency. The GYY4137 is a widely used H2S donor that releases a low amount of H2S over a prolonged period to mimic physiological production (Li et al., 2008). Because H2S discharge is unusually sluggish by GYY4137, the final concentration of H2S released is likely to be significantly lower than the initial concentration of GYY4137. We confirmed this by measuring H2S release in U1 cells treated with low (0.3 mM) or high (5 mM) concentrations of GYY4137 using methylene blue colorimetric assay. As a control, we treated U1 cells with 0.3 mM NaHS, which rapidly releases a high amount of H2S. As expected, NaHS treatment rapidly released 90% of H2S within 5 min of treatment (Figure 4A). In contrast, GYY4137 uniformly released a low amount of H2S for the entire 120 hr duration of the experiment (Figure 4A).
We systematically tested the effect of GYY4137 on HIV-1 reactivation using multiple models of HIV-1 latency and replication. As a control, we used N-acetyl cysteine (NAC) that is known to block HIV-1 reactivation (Roederer et al., 1990). Pretreatment of U1 with a non-toxic dose of GYY4137 (5 mM) (Figure 4—figure supplement 1A) diminished the expression of gag transcript by twofold at 24 hr and tenfold at 48 hr post-PMA treatment (Figure 4B). The effect of GYY4137 on p24 levels in the supernatant was even more striking as it completely abolished the time-dependent increase in p24 concentration post-PMA treatment (Figure 4C). As expected, pretreatment with NAC similarly prevented PMA-triggered reactivation of HIV-1 in U1 (Figure 4C). Pretreatment of U1 with spent GYY4137, which comprises the decomposed backbone, showed no effect on PMA induced gag transcript (Figure 4—figure supplement 1B). Because TNF-α is a physiologically relevant cytokine that reactivates HIV-1 from latency (Folks et al., 1987), we tested the effect of GYY4137 on TNF-α-mediated virus reactivation. Treatment of U1 with TNF-α stimulated the expression of gag transcript by 42-fold and 169-fold at 24 and 48 hr, post-treatment, respectively (Figure 4D). The addition of GYY4137 or NAC nearly abolished the reactivation of HIV-1 in response to TNF-α treatment (Figure 4D). Earlier, we showed that depletion of CTH stimulated HIV-1 reactivation in U1 (see Figure 2C). Therefore, we tested if GYY4137 could complement this genetic deficiency and subvert HIV-1 reactivation. The U1-shCTH cells were pre-treated with 5 mM GYY4137 and p24 levels in the supernatant were measured. The elevated levels of p24 in U1-shCTH were reduced by twofold under basal conditions and 3.2-fold upon PMA stimulation in response to GYY4137 (Figure 4E). Both RNAi and chemical complementation data provide evidence that H2S is one of the factors regulating HIV-1 latency and reactivation in U1.
Similar to U1, we next examined whether GYY4137 subverts HIV-1 reactivation in the J1.1 T-cell line model. Treatment of J1.1 with PMA for 12 hr resulted in a 38-fold increase in gag transcript as compared to untreated J1.1 (Figure 4F), indicating efficient reactivation of HIV-1. Importantly, pretreatment with various non-toxic concentrations of GYY4137 (Figure 4—figure supplement 1C) reduced the stimulation of gag transcription by twofold upon subsequent exposure to PMA (Figure 4F). Interestingly, low concentration of GYY4137 (0.3 mM) was relatively more effective than high concentration (5 mM) in subverting HIV-1 reactivation. While intriguing, these findings are consistent with the reports that high concentrations of H2S induce pro-oxidant effects on cellular physiology (Olas et al., 2019), which might have dampened the suppressive action of GYY4137 on HIV-1 transcription in J1.1. However, this needs further experimentation. The inhibitory effect of GYY4137 on HIV-1 reactivation was relatively greater compared to NAC in J1.1 (Figure 4F). Consistent with U1 and J1.1, treatment of J-Lat with 5 μM prostratin for 24 hr induced significant HIV-1 reactivation, which was translated as 100% increase in GFP+ cells (Figure 4—figure supplement 1D). Pretreatment with GYY4137 significantly reduced HIV-1 reactivation in a dose-dependent manner (Figure 4—figure supplement 1D).
We also examined if an endogenous increase in H2S by GYY4137 halts the replication of HIV-1 in primary CD4+ T cells. To this end, we infected primary CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) of three healthy human donors with HIV-1 (pNL4.3) and monitored HIV-1 replication by measuring the levels of p24 in the supernatant at 3 and 5 days post-infection. The p24 ELISA confirmed a time-dependent increase in viral load, which was uniformly reduced upon pretreatment with a non-toxic concentration of GYY4137 (0.8 mM) (Figure 4G and Figure 4—figure supplement 1E). Overall, these data establish that elevated levels of endogenous H2S efficiently suppress HIV-1 reactivation and replication.
GYY4137 reduced the expression of host genes involved in HIV-1 reactivation
To dissect the mechanism of GYY4137-mediated inhibition on HIV-1 reactivation, we examined the expression of 185 genes associated with HIV-1 reactivation using the NanoString nCounter Technology as described above (Figure 5A and Supplementary file 1d). Expression was analyzed for viral latency (unstimulated U1), reactivation (PMA-stimulated treated U1; PMA), and H2S-mediated suppression (U1-GYY+PMA). Consistent with the role of PMA-mediated oxidative stress in preceding HIV-1 reactivation (Bhaskar et al., 2015), expression of genes encoding ROS, and RNS generating enzymes (e.g., NADPH oxidase [NCF1 and CYBB] and Nitric oxide synthase [NOS2]) were upregulated (Figure 5A). Also, the expression of major antioxidant enzymes (e.g., GPXs, PRDXs, and CAT) and redox buffers (GSH and TRX pathways) remained repressed in U1-PMA, indicative of elevated oxidative stress. Additionally, pro-inflammatory signatures (e.g., TGFB1 and SERPINA1) and trans-activators (e.g., FOS) were induced, whereas host factors involved in HIV-1 restriction (e.g., IRF1 and YY1) were repressed in U1-PMA as compared to U1. In agreement with the reduction in endogenous H2S levels during HIV-1 reactivation, expression of CTH involved in H2S anabolism was downregulated and H2S catabolism (SQRDL) was upregulated by PMA.
-
Figure 5—source data 1
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig5-data1-v3.xlsx
-
Figure 5—source data 2
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig5-data2-v3.zip
-
Figure 5—source data 3
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig5-data3-v3.zip
-
Figure 5—source data 4
- https://cdn.elifesciences.org/articles/68487/elife-68487-fig5-data4-v3.xlsx
We noticed that the treatment with GYY4137 reversed the effect of PMA on the expression of genes associated with oxidative stress, inflammation, anti-viral response, apoptosis, and trans-activators (Figure 5A). For example, GYY4137 elicited a robust induction of genes regulated by nuclear factor erythroid 2-related factor 2 (Nrf2) in U1-GYY+PMA compared to U1 or U1-PMA (Figure 5A). Nrf2 acts as a master regulator of redox metabolism (Pall and Levine, 2015) by binding to the antioxidant response element (ARE) and initiating transcription of major antioxidant genes (e.g., GSH pathway, TXNRD1, HMOX1, GPX4, and SRXN1). Interestingly, while the expression of Nrf2-dependent CTH gene was induced in U1-GYY+PMA, MPST remained unaffected. The Nrf2 activity has been shown to pause HIV-1 infection by inhibiting the insertion of reverse-transcribed viral cDNA into the host chromosome (Furuya et al., 2016). Furthermore, sustained activation of Nrf2-dependent antioxidant response is essential for the establishment of viral latency (Shytaj et al., 2020). A few genes encoding H2O2 detoxifying enzymes (e.g., CAT, GPX1, and PRDXs) were repressed in U1-GYY+PMA, indicating that the expression of these enzymes was likely counterbalanced by the elevated expression of other antioxidant systems by H2S. In line with the antagonistic effect of GYY4137 on HIV-1 transcription, the expression of HIV-1 trans-activator (FOS) was downregulated, and an inhibitor of NF-κB signaling (NFKBIA) was induced in U1-GYY+PMA as compared to U1 or U1-PMA. Finally, GYY4137 stimulated the expression of several anti-HIV (YY1, STAT1, STAT3, and IRF1) and pro-survival factors (CDKN1A and LTBR) that were repressed by PMA (Figure 5A). Altogether, H2S supplementation induces a major realignment of redox metabolism and immune pathways associated with HIV-1 reactivation.
GYY4137-mediated modulation of the Keap1-Nrf2 axis, NF-κB signaling, and activity of epigenetic factor YY1
Our expression data indicate activation of the Nrf2 pathway and modulation of transcription factors such as NF-κB and YY1 upon treatment with GYY4137. We tested if the mechanism of H2S-mediated subversion of HIV-1 reactivation involves these pathways. H2S has recently been shown to prevent cellular senescence by activation of Nrf2 via S-persulfidation of its negative regulator Keap-1 (Yang et al., 2013). Under unstimulated conditions, Nrf2 binds to Keap1, and the latter promotes Nrf2 degradation via the proteasomal machinery (Yang et al., 2013). Nrf2 disassociates from the S-persulfidated form of Keap1, accumulates in the cytoplasm, and translocates to nuclei where it induces transcription of antioxidant genes upon oxidative stress (Yang et al., 2013). We first examined if GYY4137 treatment accumulates Nrf2 in the cytoplasm. As expected, Nrf2 was not detected in U1 owing to its association with Keap1 under unstimulated conditions. However, a noticeable accumulation of Nrf2 was observed in U1-GYY+PMA compared to U1 or U1-PMA (Figure 5B). As an additional verification, we quantified the levels of an Nrf2-dependent protein HMOX-1. Similar to Nrf2, the levels of HMOX-1 were also induced in U1-GYY+PMA (Figure 5B). These findings are consistent with our NanoString data showing activation of Nrf2-specific oxidative stress responsive genes in GYY4137 treated U1.
Next, we determined if GYY4137 treatment targets NF-κB, which is a major regulator of HIV-1 reactivation (Williams et al., 2007). The cellular level of phosphorylated serine-536 in p65, a major subunit of NF-κB, is commonly measured to assess NF-κB activation (Zhong et al., 1998). Since PMA reactivates HIV-1, we observed an increase in p65 ser-536 phosphorylation in U1-PMA (Figure 5C). In contrast, pretreatment with GYY4137 significantly decreased PMA-induced p65 ser-536 phosphorylation (Figure 5C). These findings suggest that GYY4137 is likely to affect the DNA binding and transcriptional activity of NF-κB. Consistent with this idea, a two-step chromatin immunoprecipitation and genomic qPCR (ChIP-qPCR) assay showed that GYY4137-treatment significantly reduced the occupancy of p65 at its binding site (ER, enhancer region) on the HIV-1 LTR (Figure 5D–E).
GYY4137 induces the expression of another transcription factor YY1, which binds to HIV-1 LTR at RBEI and RBEIII and recruits histone deacetylase (HDACs) to facilitate repressive chromatin modifications (Coull et al., 2000). Overexpression of YY1 is known to promote HIV-1 latency (Bernhard et al., 2013). We tested if GYY4137 promotes the binding of YY1 at RBEI and RBEIII sites on HIV-1 LTR by ChIP-qPCR. The occupancy of YY1 at RBEI and RBEIII was significantly enriched in the case of U1-GYY+PMA as compared to U1-PMA or U1 (Figure 5F). Taken together, these results indicate that increasing endogenous H2S levels by using a slow-releasing donor effectively modulate the Keap1-Nrf2 axis and activity of transcription factors to maintain redox balance and control HIV-1 reactivation.
GYY4137 blocks HIV-1 rebound from latent CD4+ T cells isolated from infected individuals on suppressive ART
Having shown that H2S suppresses HIV-1 reactivation in multiple cell line models of latency, we next studied the ability of GYY4137 to limit virus transcription in primary CD4+ T cells derived from virally suppressed patients. We used a previously established methodology of maintaining CD4+ T cells from infected individuals on ART for a few weeks without any loss of phenotypic characteristics associated with HIV-1 reservoirs (Kessing et al., 2017). We isolated CD4+ T cells from PBMCs of five HIV-1 infected subjects on suppressive ART. The CD4+ T cells were expanded in the presence of interleukin-2 (IL-2), phytohemagglutinin (PHA), and feeder cells (Figure 6A). The expanded cells were cultured for 4 weeks in a medium containing IL-2 with ART (100 nM efavirenz, 180 nM zidovudine, and 200 nM raltegravir) either in the presence or absence of GYY4137 (100 μM) (Figure 6A). In this model, the virus reactivates by day 14 followed by progressive suppression at day 21 and latency establishment by day 35. The virus can be reactivated from this latent phase using well-known LRAs (Kessing et al., 2017). We quantified the temporal expression of viral RNA using reverse transcription quantitative PCR (RT-qPCR) periodically at 7-day interval. The levels of viral RNA increased initially (days 7–14), followed by low to undetectable levels by day 28 (Figure 6B). By day 28, virus RNA was uniformly untraceable in cells derived from GYY4137 treated and untreated groups, indicating the establishment of latency (Figure 6B).
We next assessed the ability of GYY4137 to efficiently block viral reactivation. On day 28, we stimulated the CD4+ T cells with the protein kinase C (PKC) activator, prostratin, in the absence of any treatment. The activation of viral transcription was measured 24 hr later by RT-qPCR. The removal of ART uniformly resulted in a viral reactivation by prostratin in CD4+ T cells of HIV1 patients (Figure 6C). In contrast, upon ART+GYY4137 removal followed by prostratin stimulation, viral reactivation was attenuated by 90% (N=5, mean) for all five patient samples, and individual inhibition ranged from 78.9% to 100% (Figure 6C). Overall, pretreatment with ART+GYY4137 significantly reduced prostratin-mediated HIV-1 reactivation when compared to ART alone (p<0.01) (Figure 6D).
We also examined the immune-phenotype of CD4+ T cells treated with ART or ART+GYY4137 by monitoring the expression of activation (CD38) and quiescence (CD127) marker. As expected, CD38 expression increased, and CD127 expression decreased at days 7 and 14 during the activation phase, followed by a gradual reversal of the pattern during the resting phase at days 21 and 28 (Figure 6E–F and Figure 6—figure supplement 1A). Interestingly, GYY4137 treatment did not alter the temporal changes in the expression of activation and quiescence markers on CD4+ T cells (Figure 6E–F). Since memory CD4+ T cells are preferentially targeted by HIV (Chomont et al., 2009; Brenchley et al., 2004), we further analyzed if the status of naive (TN), central memory (TCM), transitional memory (TTM), and effector memory (TEM) is affected by the GYY4137 in our ex vivo expansion model. We observed that the CD4+ T cells that responded to ex vivo activation were mainly composed of TTM and TEM in our patient samples (Figure 6—figure supplement 1B-E). This is consistent with the study reporting the presence of translation-competent genomes mainly in the TTM and TEM of ART-suppressed individuals (Pardons et al., 2019a). Interestingly, the fraction of TTM shows a progressive decline, whereas TEM displays gradual increase during transition from activation (7–14 days) to quiescence phase (21–28 days) (Figure 6—figure supplement 1D-E). The addition of GYY4137 did not affect dynamic changes in the frequency of TTM and TEM subpopulations (Figure 6—figure supplement 1D-E).
Finally, we tested if the reduction in viral RNA upon GYY4137 treatment is due to the loss of cells with the ability to reactivate virus or selection of cells subset that is non-responsive to reactivating stimuli. We did not find significant differences in total HIV-1 DNA content between the CD4+ T cells immediately isolated from the patient’s PBMCs (ex vivo) and the expanded cells treated with ART+ GYY4137 or ART alone for the entire duration of the experiment (Figure 6G). The viability of cells remained comparable between ART+ GYY4137 and ART treatment groups over time (Figure 6—figure supplement 1F). Moreover, we observed that prolonged treatment with GYY4137 in combination ART does not abrogate CD4+ T-cell survival and proliferative capacity in the presence of anti-CD3/anti-28 beads or Staphylococcal enterotoxin B (SEB) as T cell activation stimuli (Figure 6—figure supplement 2A-D). Additionally, GYY4137 treatment had no adverse effect on antigen (CMVpp65) specific CD4+ and CD8+ T cells activation and function upon ex vivo stimulation (Figure 6—figure supplement 2E-J and Figure 6—figure supplement 3A-B).
Altogether, using a range of cellular and immunological assays, we confirmed that the characteristics of an individual’s viral reservoir remain preserved, and the suppression of viral RNA upon GYY4137 treatment is the result of H2S-mediated inhibition of HIV-1 transcription rather than a reduction in proviral content or an altered CD4+ T cell subsets. In sum, prolonged exposure to GYY4137 results in potent inhibition of viral reactivation, suggesting a new H2S-based mechanism to neutralize bursts of virus reactivation under suppressive ART in vivo.
GYY4137 prevents mitochondrial dysfunction in CD4+ T cells of HIV-1 patients during viral rebound
Because virus reactivation upon depletion of CTH-mediated H2S generation resulted in mitochondrial dysfunction and redox imbalance in U1, we tested if the elevation of H2S levels by GYY4137 improves mitochondrial health and maintain redox homeostasis of primary CD4+ T cells during virus reactivation ex vivo. As described earlier, CD4+ T cells harboring latent virus upon prolonged (28 days) treatment of ART and ART+GYY4137 were stimulated by prostratin or left unstimulated and subjected to mitochondrial flux analysis. The unstimulated cells from both ART and ART+GYY4147 cultures did not show any difference in OCR (Figure 7A). In contrast, several features reflecting efficient mitochondrial activity such as basal respiration and ATP-coupled respiration were significantly higher in prostratin stimulated CD4+ T cells in case of ART+GYY4137 treatment than ART alone (Figure 7B–C). Consistent with this, mitoROS generation upon stimulation with prostratin or other LRAs such as PMA/ionomycin was reduced in ART+GYY4137 treated CD4+ T cells than ART alone (p=0.005 and p=0.014), and was nearly comparable to unstimulated cells (Figure 7D–E). The reduction in mitoROS could be a consequence of GYY4137-mediated increase in the expression of Nrf2-dependent antioxidant systems. We directly tested this by RT-qPCR analysis of a selected set of Nrf2-dependent genes on CD4+ T cells treated with GYY4137 for 28 days. Consistent with our findings in U1, treatment with ART+ GYY4137 uniformly induced the expression of antioxidant genes in the latently infected CD4+ T cells compared to cell treated with ART alone (Figure 7F).
Altogether, these data suggest that H2S not only prevents virus reactivation but also improves mitochondrial bioenergetics and maintains redox homeostasis, which could be important for in vivo suppression of viral rebound and replenishment of the reservoir.
Discussion
The major conclusion of our study is that HIV-1 reactivation is coupled to depletion of endogenous H2S, which is associated with dysfunctional mitochondrial bioenergetics, in particular suppressed OXPHOS, GSH/GSSG imbalance, and elevated mitoROS. Decreased H2S also impaired the expression of genes involved in the maintenance of redox balance, mitochondrial function, inflammation, and HIV-1 restriction, which correlates with reactivation of HIV-1. This conclusion is supported in multiple cell line models of HIV-1 latency. Chemical complementation with GYY4137 identified H2S as an effector molecule. Finally, we confirmed the clinical relevance of our finding in primary CD4+ T cells isolated from ART-suppressed patients to recapitulate features of HIV-1 latency and reactivation (Kessing et al., 2017). Overall, our data show that while H2S deficiency reactivates HIV-1, the H2S donor GYY4137 can potently inhibit residual levels of HIV-1 transcription during suppressive ART and block virus reactivation upon stimulation. Hence, our findings highlight that H2S based therapies (Szabó, 2007) can be exploited to lock HIV-1 in a state of persistent latency by impairing the ability to reactivate.
How does H2S promote HIV-1 latency and suppress reactivation? Several studies revealed that HIV-1 reactivation is associated with loss of mitochondrial functions, oxidative stress, inflammation, and apoptosis (Tyagi et al., 2020; Bhaskar et al., 2015; Khan et al., 2015; Badley et al., 2003). Several of these biological dysfunctions are corrected by H2S. For example, localized delivery of H2S in physiological concentrations improves mitochondrial respiration, mitigates oxidative stress, and exerts anti-inflammatory functions (Tinajero-Trejo et al., 2013; Kimura et al., 2010; Fu et al., 2012; Banerjee, 2011; Gao et al., 2012; Bhatia, 2012; Szabo et al., 2014; Szabó, 2007). Our NanoString findings, XF flux analysis, and redox measurement support a mechanism whereby H2S sufficiency promotes sustenance of mitochondrial health and redox homeostasis to control HIV-1 reactivation. Conversely, genetic depletion of endogenous H2S promotes HIV-1 reactivation by decelerating OXPHOS, GSH/GSSH imbalance, and elevated mitoROS. It is widely known that reduced OXPHOS leads to accumulation of NADH, which traps flavin mononucleotide (FMN) in the reduced state on respiratory complex I leading to mitoROS generation by incomplete reduction of O2 (Murphy, 2009). Also, H2S-depletion increased nmOCR, which indicates elevated activities of other ROS producing enzymes such as NADPH oxidase and cyclooxygenases/lipoxygenase (Kim et al., 2008; Chacko et al., 2014). All of these metabolic changes are likely contributors of overwhelming ROS and disruption of GSH/GSSG poise in U1-shCTH, resulting in HIV-1 reactivation. In fact, consistent with our findings, oxidative shift in GSH/GSSG poise, deregulated mitochondrial bioenergetics, and ROI has been reported to promote HIV-1 reactivation (Tyagi et al., 2020; Bhaskar et al., 2015). The addition of GYY4137 stimulated OXPHOS and blocked HIV-1 reactivation, which is in line with the known ability of H2S in sustaining respiration by acting as a substrate of cytochrome C oxidase (CcO) (Szabo et al., 2014). Also, H2S can prevent mitochondria-mediated apoptosis (Hu et al., 2009), which is crucial for HIV-1 reactivation and infection (Khan et al., 2015). Finally, activation of Nrf2-specific antioxidant pathways upon exposure to GYY4137 agrees with the potential of H2S in augmenting the cellular antioxidative defense machinery (Pal et al., 2018; Kimura et al., 2010; Banerjee, 2011). Importantly, cell lines (U1 and J1.1) modeling HIV-1 latency and PBMCs of individuals that naturally suppress HIV-1 reactivation (long-term non-progressors [LTNPs]) display robust capacities to resist oxidative stress and apoptosis (Bhaskar et al., 2015; Cohen et al., 2004).
Our transcription profiling showed a positive correlation between GYY4137-induced H2S sufficiency and HIV-1 restriction factors (e.g., YY1, APOBEC3, IRF1, and Nrf2) and negative correlation with HIV-1 trans-activators (e.g., NFKB and FOS), consistent with an interrelationship between cell metabolism and HIV-1 latency (Valle-Casuso et al., 2019; Castellano et al., 2019). Interestingly, a sustained induction of Nrf2-driven cellular antioxidant response is essential for the successful transition between productive and latent HIV-1 infection (Bhaskar et al., 2015; Shytaj et al., 2020). Moreover, inhibition of Nrf2 promoted viral transcription and increased ROS generation (Shytaj et al., 2020), whereas its activation reduced HIV-1 infection (Furuya et al., 2016). On this basis, we think that H2S-mediated inhibition of HIV-1 is partly related to the activation of Nrf2-dependent antioxidant genes. In HIV-1 infection, the suppression of viral reactivation and pro-inflammatory mediator expression was paralleled by the inhibition of NF-κB. Interestingly, H2S inhibited activation of NF-κB in several models of inflammatory diseases, including hemorrhagic shock, lung injury, and paramyxovirus infections (Cao et al., 2014; Li et al., 2015). Further, recent studies have highlighted the anti-viral and anti-inflammatory role of H2S in SARS-CoV-2 infection and envisage the possibility of including H2S donors in COVID-19 therapy (Renieris et al., 2020; Citi et al., 2020; Pozzi et al., 2021). Similarly to these findings, we found that exposure of U1 with GYY4137 inhibited the NF-κB p65 subunit and reduced its binding to HIV-1 LTR. Currently, no antiretroviral drugs inhibit basal transcription of provirus and blocks reactivation upon therapy (ART) interruption. It has been suggested that epigenetic silencing will be an important prerequisite for persistent latency (Lange et al., 2020; Kumar et al., 2015). Our expression and ChIP-qPCR data suggest that H2S could exert its influence on HIV-1 replication machinery via activating YY1- an epigenetic silencer of HIV-1 LTR (Coull et al., 2000; Bernhard et al., 2013). Interestingly, another gasotransmitter NO modulates YY1 function via S-nitrosylation of its cysteine residues (Bonavida and Baritaki, 2012), indicating that YY1 is amenable to thiol-based-modifications and raises the possibility of YY1 S-persulfidation by H2S as a mechanism to epigenetically reconfigure HIV-1/promoter LTR.
The inefficiency of current ART in preventing virus rebound after therapy cessation poses a major hurdle to HIV-1 cure. Using a primary cell system that has been successfully used to recapitulate latency and reactivation seen in patients (Kessing et al., 2017), we confirmed that pretreatment with GYY4137 attenuated viral rebound in primary human CD4+ T cells upon stimulation with prostratin. Collectively, our results suggest that H2S reduces HIV-1 transcriptional activity, promotes silencing of its promoter, and reduces its potential for reactivation. The virus-suppressing effects of H2S were observed alongside its beneficial consequences on cellular physiology (e.g., mitochondrial function and redox balance). Both mitochondrial dysfunction and oxidative stress are major complications associated with long-term exposure to ART and contribute to inflammation and organ damage (Ibeh and Emeka-Nwabunnia, 2012; Hulgan and Gerschenson, 2012; Reyskens et al., 2013). Future studies will investigate if the prolonged treatment with H2S donors results in a better outcome due to recruitment of specific repressor and/or epigenetic silencer of HIV-1 LTR without detrimental consequences on cellular physiology. In this context, it is important to carefully calibrate the concentration of H2S donors. The higher concentration of H2S is associated with toxicity and side effects (Shen et al., 2015), whereas lower micro molar concentrations are beneficial (Szabo et al., 2014). The absorption and metabolism are reasonably well characterized for exogenously administered high doses of H2S (Reiffenstein and Roth, 1992; Beauchamp et al., 1984). The sulfide oxidation pathways are involved in the oxidation of excess H2S to thiosulfate and sulfate, which are cleared from the body via the urine in free or conjugated form (Kage et al., 1997). These observations will be important for exploring future possibilities to use H2S donors in clinical settings. Importantly, several H2S donors are currently being tested in phase 2 and phase 3 human clinical trials for other indications (Wallace et al., 2020; Polhemus et al., 2015).
Blocking HIV-1 rebound by inhibitors of viral factors (e.g., Tat) invariably results in the emergence of resistant mutants (Mousseau et al., 2019). In this context, blocking HIV-1 rebounds via H2S-directed modulation of host pathways could help in overcoming the problem of evolution of escape variants. In conclusion, we identify H2S as a central factor in HIV-1 reactivation. Our systematic mechanistic dissection of the role of H2S in cellular bioenergetics, redox metabolism, and latency unifies many previous phenomena associated with viral persistence.
Materials and methods
Study design
Request a detailed protocolThe primary objective of this study was to understand the role H2S gas in modulating HIV-1 latency and reactivation. First, we examined the differential expression of enzymes involved in H2S biogenesis and levels of H2S upon HIV-1 latency and reactivation. Next, we genetically silenced the expression of the main H2S producing gene CTH and showed its importance in maintaining HIV-1 latency. We performed detailed mechanistic studies on understanding the role of CTH in regulating cellular antioxidant response, mitochondrial respiration, ROS generation to maintain HIV-1 latency. Finally, pharmacological donor of H2S (GYY4137) was used to reliably increase endogenous H2S levels and to study its consequence on HIV-1 latency and rebound. Primary CD4+ T cells derived from ART-treated HIV-1 infected patients were used to assess the effect of GYY4137 in modulating HIV-1 rebound by improving mitochondrial bioenergetics and mitigating redox stress.
Mammalian cell lines and culture conditions
Request a detailed protocolThe human pro-monocytic cell line U937, CD4+ T lymphocytic cell line Jurkat, HEK293T were procured from ATCC, Manassas, VA. The chronically infected U1, J1.1, ACH-2, J-Lat 6.3, J-Lat 10.6, and TZM-bl cell lines were obtained through NIH HIV Reagent Program, Division of AIDS, NIAID, NIH, USA. All cell lines are verified to be mycoplasma free by EZdetect PCR Kit for Mycoplasma Detection (HIMEDIA). The cell lines were cultured in RPMI 1640 (Cell Clone) supplemented with L-glutamine (2 mM), 10% fetal bovine serum (FBS; MP Biomedicals), penicillin (100 units/ml), streptomycin (100 μg/ml) at 37°C and 5% CO2. HEK293T and TZM-bl cells were cultured in Dulbecco’s modified Eagle’s medium (Cell Clone) supplemented with 10% FBS.
Chemical reagents
Request a detailed protocolSodium hydrosulfide (NaHS), morpholin-4-ium 4-methoxphenyl(morpholino) phosphinodithioate dichloromethane complex (GYY4137), Phorbol-12-myristate-13-acetate (PMA), N-acetyl cysteine (NAC), Prostratin, DL-Propargylglycine (PAG), and L-Cysteine were purchased from Sigma-Aldrich. Recombinant human TNF-α was purchased from InvivoGen. The antiretroviral drugs efavirenz, zidovudine, raltegravir, and lamivudine were obtained through the NIH HIV Reagent Program.
Latent viral reactivation
Request a detailed protocolLatently infected U1, J1.1, and J-Lat 10.6 (2×105 cells/ml) were stimulated with PMA (5 ng/ml) or TNF-α (100 ng/ml) for the time indicated in the figure legends. HIV-1 reactivation was determined by intracellular gag RT-qPCR or p24 estimation in supernatant by HIV-1 p24 ELISA (J. Mitra and Co. Pvt. Ltd., India). J-Lat 6.3 cells were stimulated with Prostratin (2.5 μM) for 24 hr and HIV-1 reactivation was assessed by estimating GFP+ cells (excitation: 488 nm; emission: 510 nm) using BD FACSVerse flow cytometer (BD Biosciences). The data were analyzed using FACSuite software (BD Biosciences).
Reverse transcription quantitative PCR
Request a detailed protocolTotal cellular RNA was isolated by RNeasy Mini Kit (QIAGEN), according to the manufacturer’s protocol. RNA (500 ng) was reverse transcribed to cDNA (iScript cDNA Synthesis Kit, Bio-Rad), subjected to quantitative real-time PCR (iQ SYBR Green Supermix, Bio-Rad), and performed using the Bio-Rad C1000 real-time PCR system. HIV-1 reactivation was assessed using gene-specific primers (Supplementary file 1f). The expression level of each gene is normalized to human β-actin as an internal reference gene.
Western blot analysis
Request a detailed protocolTotal cell lysates of PMA-treated and untreated U1, J1.1, U937, and Jurkat cell lines were prepared using radioimmunoprecipitation (RIPA) lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS [sodium dodecyl sulfate], 1× protease inhibitor cocktail (Sigma-Aldrich), 1× phosphatase inhibitor cocktail [Sigma-Aldrich]). After incubation on ice for 20 min, the lysates were centrifuged at 12,000 rpm, 4°C for 15 min. Clarified supernatant was taken and total protein concentration was determined by Bicinchoninic Acid Assay (Pierce, Thermo Fisher Scientific). Total protein extracts were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes. Membranes were probed with an anti-CBS (EPR8579), CTH (ab151769), MPST (ab154514), and anti-HIV-1 p24 (ab9071) from Abcam; Nrf2 (CST-12721), Keap1 (CST-4678), NF-κB p65 (CST-6956), phospho-NF-κB p65 (Ser536) (CST-3033), YY1 (CST-63227), and GAPDH (CST-97166) from Cell Signaling Technologies, Inc; and anti-rabbit IgG (CST-7074) and anti-mouse IgG (CST-7076) were used a secondary antibody. Proteins were detected by ECL and visualized by chemiluminescence (PerkinElmer, Waltham, MA) using the Bio-Rad Chemidoc Imaging system (Hercules, CA). For membrane reprobing, stripping buffer was used (2% SDS [w/v], 62 mM Tris-Cl buffer [0.5 M, pH 6.7] and 100 mM β-mercaptoethanol) for 20 min at 55°C. After extensive washing with phosphate-buffered saline (PBS) containing 0.1% Tween 20 (Sigma-Aldrich), membrane was blocked and reincubated with desired antibodies.
H2S detection assays
Request a detailed protocolEndogenous H2S levels of U1 and U937 cells were detected using H2S specific fluorescent probe as described (Chen et al., 2013). Briefly, cells were treated with PMA (5 ng/ml) for 24 hr, washed with 1× PBS, and stained with 200 μM 7-Azido-4-Methylcoumarin (AzMC) (Sigma-Aldrich). The stained cells were mounted on a glass slide and visualized using Leica TCS SP5 confocal microscope (excitation: 405 nm; emission: 450 nm). Images obtained were analyzed using LAS AF Lite software (Leica Microsystems) and semi-quantification of 50 cells was performed using ImageJ software.
H2S generation was also measured using methylene blue assay. The supernatant of U1 cells treated with NaHS or GYY4137 was incubated with Zinc acetate (1%) and NaOH (3%) (1:1 ratio) to trap H2S for 30 min. The reaction was terminated using 10% trichloroacetic acid solution. Following this, reactants were incubated with 20 mM N,N-dimethylphenylendiamine (NNDPD) in 7.2 M HCl and 30 mM FeCl3 in 1.2 M HCl for 30 min and absorbance was measured at 670 nm. The concentration of H2S was determined by plotting absorbance on a standard curve generated using NaHS (0–400 μM; R2=0.9982).
Stable cell line generation
Request a detailed protocolFor generating CBS and CTH knockdown in U1 and J1.1 cells, we used validated pooled gene-specific shRNAs from the RNAi Consortium (TRC) library (Sigma-Aldrich, USA; shRNA sequences given in Supplementary file 1a). The lentiviral particles were generated in HEK293T cells using the packaging vectors, psPAX2 and pMD2.G. The pLKO.1-puro vector encoding a non-mammalian targeting shRNA (shNT) was used as a control. The U1 cells were transduced with lentiviral particles in opti-MEM containing polybrene (10 μg/ml) for 6 hr. Cells were washed and stable clones were selected in culture medium containing 250 ng/ml of puromycin. Total RNA or cell lysates were prepared to validate knockdown of CBS and CTH.
Intracellular HIV-1 P24 staining
Request a detailed protocolFor intracellular p24 staining, U1-shCTH and U1-shNT cells were stimulated with PMA (5 ng/ml), washed with PBS followed by fixation and permeabilization using a fixation and permeabilization kit (eBiosciences). Permeabilized cells were then incubated with 50 μl of 1:100 dilution of phycoerythrin (PE)-conjugated mouse anti-p24 monoclonal antibody (KC57-RD1; Beckman Coulter, Inc) for 30 min at room temperature. After incubation, the cells were washed two times and the fluorescence of stained samples was acquired using BD FACSVerse flow cytometer (BD Biosciences). The data were analyzed using FACSuite software (BD Biosciences).
Cysteine estimation
Request a detailed protocolThe quantification of cysteine was determined using Cysteine assay kit (Sigma-Aldrich). U1-shNT and U1-shCTH cells (107 cells) were harvested and lysed by sonication in assay buffer on ice. Lysates were clarified by centrifugation at 12,000 rpm, 4°C for 10 min. Then, 10 μl of sample was added to each well and incubated with enzyme mix and detection reagent as per the manufacturer’s instruction. The assay plate was read using fluorescence plate reader at Ex/Em=365/450 nm in kinetic mode at room temperature. The concentration of cysteine in sample was calculated from standard curve.
Cysteine deprivation and HIV-1 reactivation
Request a detailed protocolU1 cells (2×105 cells/ml) were cultured in complete RPMI 1640 medium containing 208.16 μM L-cystine (as cysteine source) and 100 μM L-methionine (denoted as [+Cys]) or RPMI 1640 medium without L-methionine and L-cystine (Sigma-Aldrich, Cat #7513) supplemented with 100 μM L-methionine (Sigma-Aldrich, Cat #64319) (denoted as cysteine-free RPMI [−Cys]), 10% dialyzed FBS (Gibco), penicillin (100 units/ml), and streptomycin (100 μg/ml). Cells were harvested at indicated time points and viral reactivation was analyzed by gag RT-qPCR.
NanoString nCounter assay
Request a detailed protocolTotal RNA was isolated using a RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. RNA concentration and purity were measured using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA), bioanalyzers systems (Agilent Technologies, Inc), and Qubit assays (Thermo Fisher Scientific). An nCounter gene expression assay was performed according to the manufacturer’s protocol. The assay utilized a custom-made NanoString codeset designed to measure 185 genes, including six house-keeping genes (Supplementary file 1b). This custom-made panel included genes associated with oxidative stress and HIV-1 infection (Supplementary file 1b). All genes were assayed simultaneously in multiplexed reactions and analyzed by fully automated nCounter Prep Station and digital analyzer (NanoString Technologies). The data were normalized to B2M, used as a housekeeping gene due to its minimum % CV across the samples, and analysis was done using nSolver 4.0 software.
Measurement of oxygen consumption rates
Request a detailed protocolOCRs were measured using a Seahorse XFp extracellular flux analyzer (Agilent Technologies) as per the manufacturer’s instructions. Briefly, cells (U1 or Primary CD4+ T cells) were seeded at a density of 104–105 per well in a Seahorse flux analyzer plate precoated with Cell-Tak (Corning). Cells were incubated for 1 hr in a non-CO2 incubator at 37°C before loading the plate in the seahorse analyzer. To assess mitochondrial respiration, three OCR measurements were performed without any inhibitor in XF assay media to measure basal respiration, followed by sequential addition of oligomycin (1 μM), an ATP synthase inhibitor (complex V), and three OCR measurements to determine ATP-linked OCR and proton leakage. Next, cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP; 0.25 μM), was injected to determine the maximal respiration rate and the SRC. Finally, rotenone (0.5 μM) and antimycin A (0.5 μM), inhibitors of NADH dehydrogenase (complex I) and cytochrome c - oxidoreductase (complex III), respectively, were injected to completely shut down the ETC to analyze nmOCR. Seahorse data were normalized to total amount of protein (μg) and mitochondrial respiration parameters were analyzed using Wave Desktop 2.6 software (Agilent Technologies).
Estimation of intracellular glutathione content and ROS
Request a detailed protocolTotal cell lysate was prepared from 107 cells using sonication in MES (2-(N-morpholino) ethanesulfonic acid) buffer. Lysates were clarified by centrifugation and total protein concentration was estimated using BCA assay. Total glutathione, reduced glutathione (GSH), and oxidized glutathione (GSSG) were measured using the glutathione assay kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s instructions. To measure ROS, cells were loaded with 10 μM of CM-H2DCFDA (excitation: 492 nm; emission; 517 nm) or 5 μM of MitoSOX Red (excitation: 510 nm; emission; 580 nm) for 30 min at 37°C and exposed to H2O2 (100 μM) or antimycin A (2 μM) or PMA (5 ng/ml) or left untreated at 37°C and 5% CO2. The fluorescence of stained samples was acquired using BD FACSVerse flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (BD Biosciences).
Virus production
Request a detailed protocolHIV-1 particle production was carried out using Lipofectamine 2000 transfection reagent (Invitrogen, Life Technologies), according to the manufacturer’s protocol, in HEK293T cells using HIV-1 NL4-3 DNA (NIH HIV Reagent Program, Division of AIDS, NIAID, NIH). The medium was replaced with fresh medium at 6 hr post-transfection, and supernatants were collected after 60 hr, centrifuged (10 min, 200×g, room temperature), and filtered through a 0.45-μm-pore-size membrane filter (MDI; Membrane Technologies) to clear cell debris. Virus was concentrated using 5× PEG-it (System Biosciences) as per the manufacturer’s protocol and virus pellet obtained was aliquoted in opti-MEM and stored at –80°C. Viral titration was done using HIV-1 reporter cell line, TZM-bl (NIH HIV Reagent Program) as described earlier (Cherne et al., 2019).
Chromatin immunoprecipitation and quantitative genomic PCR
Request a detailed protocolThe chromatin immunoprecipitation (ChIP) assays were performed using SimpleChIP Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling Technologies, Inc, MA) according to the manufacturer’s instructions. Briefly, 107 U1 cells were pre-treated with GYY4137 (5 mM) for 6 hr or left untreated and then stimulated with PMA (30 ng/ml) for 4 hr. Cells were fixed using 1% formaldehyde, neutralized with glycine, and harvested in ice-cold PBS. Cells were lysed and nuclei were sheared by sonication using Bioruptor Pico (Diagenode Inc) to obtain DNA fragments of 200–500 nucleotides. The clarified lysates were immunoprecipitated using ChIP-grade anti-NF-κB p65 (CST-6956) or anti-YY1 (CST-63227), or normal rabbit IgG (as a negative control) for overnight at 4°C followed by incubation with ChIP-grade protein G magnetic beads at 4°C for 4 hr. Chromatin was eluted from protein G beads, reverse-cross linked, and DNA was column purified. Quantitative genomic PCR was done by SYBR green-based real-time PCR using primers spanning the ER, RBE I, and RBE III regions on HIV-1 LTR. The GAPDH gene was used as the reference gene to see non-specific binding. Total input (10%) was used to normalize equal amount of chromatin taken across the samples. The relative proportion of co-immunoprecipitated DNA fragments were determined with the help of threshold cycle (CT) values for each qPCR product using the equation (100×2[CT(input-3.32)- CT(IP)]). The data obtained were represented as fold enrichment normalized to IgG background for each IP reaction.
Subject samples
Request a detailed protocolPBMCs were collected from five HIV-1 seropositive subjects on stable suppressive ART and three healthy HIV-seronegative donors (Supplementary file 1e). All subject signed informed consent forms approved by the Indian Institute of Science, Bangalore and Bangalore Medical College and Research Institute (BMCRI) review boards (Institute human ethics committee [IHEC] No-3-14012020). The PBMCs isolated from blood samples using Histopaque-1077 (Sigma-Aldrich) density gradient centrifugation was used for CD4+ T cells purification. The CD4+ T cells were purified from 50×106 PBMCs using EasySep Human CD4+ T cell isolation kit (STEMCELL Technologies).
Infection of primary CD4+ T cells
Request a detailed protocolPrimary CD4+ T cells were cultured for 3 days after isolation in RPMI 1640 supplemented with 10% FBS, 100 U/ml interleukin-2 (IL-2; PROLEUKIN; NOVARTIS), and activated by adding the Dynabeads Human T-Activator CD3/CD28 using a bead/cell ratio of 1:2. Post-activation CD4+ T cells were pre-treated with 800 μM GYY4137 for 6 hr, and infected with HIV-NL4.3 (1 ng p24/ 106 cells) by spinoculation at 1000×g for 90 min at 32°C. Following infection, cells were washed and cultured in the presence or absence of 800 μM GYY4137 in complete media containing 100 U/ml IL-2. To quantify the virion release, supernatant was harvested from infected cells and centrifuged at 400×g for 10 min and virus concentration was estimated by HIV-1 p24 ELISA (J. Mitra and Co. Pvt. Ltd., India) according to the manufacturer’s instruction.
Generation of expanded primary CD4+ T cells from aviremic subjects
Request a detailed protocolPrimary CD4+ T cells from five ART suppressed, aviremic HIV-1 infected donors were cultured at 37°C in a 5% (v/v) CO2 humidified atmosphere in RPMI 1640 medium (Gibco) with GlutaMAX, HEPES, 100 U/ml IL-2, 1 μg/ml Remel phytohemagglutinin (PHA) (Thermo Fisher Scientific), gamma-irradiated feeder PBMCs (healthy control) and either ART alone (100 nM efavirenz, 180 nM zidovudine, and 200 nM raltegravir) or ART +100 μM GYY4137. After 7 days, CD4+ T cells were cultured only with ART alone or ART+GYY4137 and 100 U/ml IL-2. For stimulation experiments on day 28, ART and ART+GYY4137 were washed off and 1×106 cells were treated with 1 µM prostratin for 24 hr.
HIV-1 RNA and DNA isolation from primary CD4+ T cells
Request a detailed protocolCD4+ T cells (1×106) from ART or ART+GYY4137 treated groups were harvested to isolate total RNA using Qiagen RNAeasy isolation kit and 200 ng of total RNA was reverse transcribed (iScript cDNA synthesis kit, Bio-Rad). Reverse transcribed cDNA was diluted tenfold and amplified using primers against HIV-1 LTRs and seminested—PCR was performed using primers and probe listed in Supplementary file 1f. Serially diluted pNL4.3 plasmid was used to obtain the standard curve. Isolation and RT-qPCR of total HIV-1 DNA were performed as described earlier (Kessing et al., 2017). Briefly, 1×106 cells were lysed (10 mM Tris-HCl, 50 nM KCl, 400 mg/ml proteinase K) at 55°C for 16 hr followed by inactivation at 95°C for 5 min. Digested product was used as a template to set up the first PCR with Taq polymerase (NEB), 1× Taq buffer, dNTPs, HIV-1 and CD3 primers for 12 cycles. The second-round amplification was done using seminested PCR strategy wherein tenfold dilution of first round PCR product was used as a template, HIV-1, and CD3 primers/probes, Taqman Fast Advance master mix (Applied Biosystems) using SetupOnePlus Real-time PCR system (Applied Biosystems). DNA isolated from ACH2 cells that contain a single copy of HIV-1 per cell was used to obtain standard curve.
Surface marker analysis of primary CD4+ T cells derived from HIV-1 patients
Request a detailed protocolCD4+ T cells derived from HIV-1 infected patients were stained for surface markers using monoclonal antibodies: CD4-BUV395 (SK3), CD45RA-APC-H7 (HI100), CD27-BV785 (O323), CCR7-Alexa 647 (G043H7), CD38-PE-Cy5 (HIT2), and CD127-PerCP-Cy5.5 (eBioRDR5). Additionally, cells were stained with Live/Dead fixable Aqua dead cell stain or AviD (Invitrogen) to exclude dead cells from the analysis as per the manufacturer’s instructions. PBMCs from HIV positiveART-treated patients were incubated with ART or ART in combination with 100 μM GYY4137 and either left unstimulated or stimulated with either CMVpp65 (JPT Technologies) or anti-CD3/anti-CD28 beads (at a bead:cell ratio of 0.25:1) for 18 hr. Cells were stained with antibodies for analysis of cell surface markers CD3-BV570 (UCHT1), CD4-FITC (RPA-T4), CD8-PerCP-Cy5.5 (SK1), CD25-BV421 (M-A251), CD69-PE (L78), and intracellular cytokines IFNγ-Alexa Fluor 700 (B27) and IL-2-APC (MQ1-17H12). Stained samples were run on BD FACSAria Fusion flow cytometer (BD Biosciences, San Jose, CA) and data were analyzed with FlowJo version 9.9.6 and v10 (Treestar, Ashland, OR).
Cell proliferation assay
Request a detailed protocolPHA/IL-2 expanded CD4+ T cell lines cultured for 14 days in the presence of ART or ART in combination with 100 μM GYY4137 were washed and rested overnight. Cells were labeled with 0.5 μM cell trace violet (CTV) (Invitrogen) and incubated at 37°C for 7 min in the dark, after which CTV uptake was stopped by addition of 5 ml ice-cold complete RPMI media. Cells were pelleted down washed once with complete RPMI and used in the cell proliferation assay. CTV-labeled cells were seeded at a density of 0.5×106/well and stimulated with either 1.7 μg/ml CMVpp65 (JPT Technologies), anti-CD3/anti-CD28 T cell activator beads at a bead:cell ratio of 0.25:1 (Thermo Fisher Scientific) or 100 ng/ml SEB (Sigma-Aldrich). After 3 days, IL-2 (20 U/ml) supplemented medium was added to the cells and cultured for another 2 days. Proliferation was measured by CTV dilution after 5 days by flow cytometry. In some experiments, after 5 days of culture CTV-labeled cells were pelleted and stained with antibodies to CD3, CD4, and CD25 and CD25 expression was analyzed by flow cytometry.
Statistical analysis
Request a detailed protocolAll statistical analyses were performed using GraphPad Prism software for Macintosh (version 9.0.0). The data values are indicated as mean ± S.D. For statistical analysis Student’s t-test (in which two groups are compared) and one-way or two-way ANOVA (for analysis involving multiple groups) were used. For flow cytometry experiments, data are represented as means ± SEM and p-value between paired samples was determined by Wilcoxon matched-pairs signed-rank test. Analysis of NanoString data was performed using the nSolver platform. Differences in p-values <0.05 and fold change >1.5 were considered significant.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2 and 5.
References
-
Mitochondrion-mediated apoptosis in HIV-1 infectionTrends in Pharmacological Sciences 24:298–305.https://doi.org/10.1016/S0165-6147(03)00125-1
-
Hydrogen sulfide: redox metabolism and signalingAntioxidants & Redox Signaling 15:339–341.https://doi.org/10.1089/ars.2011.3912
-
A critical review of the literature on hydrogen sulfide toxicityCritical Reviews in Toxicology 13:25–97.https://doi.org/10.3109/10408448409029321
-
Measuring glutathione redox potential of HIV-1-infected macrophagesThe Journal of Biological Chemistry 290:1020–1038.https://doi.org/10.1074/jbc.M114.588913
-
Role of hydrogen sulfide in the pathology of inflammationScientifica 2012:159680.https://doi.org/10.6064/2012/159680
-
Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF-κB, YY1 and SnailForum on Immunopathological Diseases and Therapeutics 3:125–133.https://doi.org/10.1615/ForumImmunDisTher.2012006065
-
Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2 S donors in COVID-19 therapyBritish Journal of Pharmacology 177:4931–4941.https://doi.org/10.1111/bph.15230
-
The Biology of the HIV-1 Latent Reservoir and Implications for Cure StrategiesCell Host & Microbe 27:519–530.https://doi.org/10.1016/j.chom.2020.03.014
-
CD8+ T cells in HIV control, cure and preventionNature Reviews. Immunology 20:471–482.https://doi.org/10.1038/s41577-020-0274-9
-
Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 inductionJournal of Immunology 176:4252–4257.https://doi.org/10.4049/jimmunol.176.7.4252
-
An exogenous hydrogen sulphide donor, NaHS, inhibits the nuclear factor κB inhibitor kinase/nuclear factor κb inhibitor/nuclear factor-κB signaling pathway and exerts cardioprotective effects in a rat hemorrhagic shock modelBiological & Pharmaceutical Bulletin 35:1029–1034.https://doi.org/10.1248/bpb.b110679
-
Changes in plasma amino acid concentrations in response to HIV-1 infectionClinical Chemistry 40:785–789.
-
HIV and mitochondria: more than just drug toxicityThe Journal of Infectious Diseases 205:1769–1771.https://doi.org/10.1093/infdis/jis105
-
Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cellsJournal of Virology 81:3477–3486.https://doi.org/10.1128/JVI.01552-06
-
Increased oxidative stress condition found in different stages of HIV disease in patients undergoing antiretroviral therapy in Umuahia (Nigeria)Immunopharmacology and Immunotoxicology 34:1060–1066.https://doi.org/10.3109/08923973.2012.681327
-
The usefulness of thiosulfate as an indicator of hydrogen sulfide poisoning: three casesInternational Journal of Legal Medicine 110:220–222.https://doi.org/10.1007/s004140050071
-
Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondriaAntioxidants & Redox Signaling 12:1–13.https://doi.org/10.1089/ars.2008.2282
-
Epigenetic crosstalk in chronic infection with HIV-1Seminars in Immunopathology 42:187–200.https://doi.org/10.1007/s00281-020-00783-3
-
Understanding frailty, aging, and inflammation in HIV infectionCurrent HIV/AIDS Reports 12:25–32.https://doi.org/10.1007/s11904-014-0247-3
-
Role of hydrogen sulfide in paramyxovirus infectionsJournal of Virology 89:5557–5568.https://doi.org/10.1128/JVI.00264-15
-
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunctionFree Radical Biology & Medicine 94:218–229.https://doi.org/10.1016/j.freeradbiomed.2016.03.003
-
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitroThe Journal of Clinical Investigation 96:456–464.https://doi.org/10.1172/JCI118056
-
Hydrogen sulfide is an endogenous potentiator of T cell activationThe Journal of Biological Chemistry 287:4211–4221.https://doi.org/10.1074/jbc.M111.307819
-
Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and Therapeutic AspectsBritish Journal of Pharmacology 171:2123–2146.https://doi.org/10.1111/bph.12368
-
How mitochondria produce reactive oxygen speciesThe Biochemical Journal 417:1–13.https://doi.org/10.1042/BJ20081386
-
Nrf2, a master regulator of detoxification and also antioxidant, anti-inflammatory and other cytoprotective mechanisms, is raised by health promoting factorsSheng Li Xue Bao: [Acta Physiologica Sinica] 10:1–18.
-
An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulationJournal of Immunology 147:3145–3148.
-
Toxicology of hydrogen sulfideAnnual Review of Pharmacology and Toxicology 32:109–134.https://doi.org/10.1146/annurev.pa.32.040192.000545
-
N-acetylcysteine: potential for AIDS therapyPharmacology 46:121–129.https://doi.org/10.1159/000139037
-
Modulation of human immunodeficiency virus 1 replication by interferon regulatory factorsThe Journal of Experimental Medicine 195:1359–1370.https://doi.org/10.1084/jem.20010753
-
The Cardioprotective Effects of Hydrogen Sulfide in Heart Diseases: From Molecular Mechanisms to Therapeutic PotentialOxidative Medicine and Cellular Longevity 2015:925167.https://doi.org/10.1155/2015/925167
-
Antioxidant nanozyme counteracts HIV-1 by modulating intracellular redox potentialEMBO Molecular Medicine 13:e13314.https://doi.org/10.15252/emmm.202013314
-
Hydrogen sulphide and its therapeutic potentialNature Reviews. Drug Discovery 6:917–935.https://doi.org/10.1038/nrd2425
-
Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and Physiological MechanismsBritish Journal of Pharmacology 171:2099–2122.https://doi.org/10.1111/bph.12369
-
Multiple organ failure during primary HIV infectionClinical Infectious Diseases 44:e28–e29.https://doi.org/10.1086/510683
-
A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drugBritish Journal of Pharmacology 177:769–777.https://doi.org/10.1111/bph.14641
-
SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial CellsAntioxidants & Redox Signaling 24:329–343.https://doi.org/10.1089/ars.2015.6331
-
Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2Antioxidants & Redox Signaling 18:1906–1919.https://doi.org/10.1089/ars.2012.4645
Article and author information
Author details
Funding
The Wellcome Trust DBT India Alliance (IA/S/16/2/502700)
- Amit Singh
Department of Biotechnology, Ministry of Science and Technology, India (BT/PR13522/COE/34/27/2015 BT/PR29098/Med/29/1324/2018 and BT/HRD/NBA/39/07/2018-19)
- Amit Singh
Department of Biotechnology, Ministry of Science and Technology, India (22-0905-0006-05-987 436)
- Amit Singh
Infosys Foundation (CIDR)
- Amit Singh
Department of Science and Technology (DST-FIST)
- Amit Singh
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
The authors are grateful to Prof. C Grundner at the Seattle Children’s Research Institute for critical reading of the manuscript and valuable input. The authors acknowledge Prof. D K Saini at Department of Molecular Reproduction, Development and Genetics, IISc for providing shRNA constructs used in this study. The authors are grateful to Ms. S Kumar and Dr. N R Sundaresan at Department of Microbiology and Cell Biology, IISc for helping with ChIP experiments carried out in this study. The authors gratefully acknowledge the NanoString services provided by TheraCUES Innovations Pvt Ltd, Bangalore. This work was supported by Wellcome Trust-Department of Biotechnology (DBT) India Alliance grant IA/S/16/2/502700 (AS) and in part by DBT grants BT/PR13522/COE/34/27/2015, BT/PR29098/Med/29/1324/2018, and BT/HRD/NBA/39/07/2018–19 (AS), DBT-IISc Partnership Program grant 22-0905-0006-05-987 436, Infosys Foundation, and DST-FIST. AS is a senior fellow of Wellcome Trust-DBT India Alliance. VKP is grateful to Indian Institute of Science for fellowship.
Ethics
Peripheral blood mononuclear cells (PBMCs) were collected from five aviremic HIV-seropositive subjects on stable suppressive ART. All subjects provided signed informed consent approved by the Indian Institute of Science, and Bangalore Medical College and Research Institute review boards (IHEC No.- 3-14012020).
Copyright
© 2021, Pal et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,592
- views
-
- 314
- downloads
-
- 5
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Lipopolysaccharides (LPS) confer resistance against harsh conditions, including antibiotics, in Gram-negative bacteria. The lipopolysaccharide transport (Lpt) complex, consisting of seven proteins (A-G), exports LPS across the cellular envelope. LptB2FG forms an ATP-binding cassette transporter that transfers LPS to LptC. How LptB2FG couples ATP binding and hydrolysis with LPS transport to LptC remains unclear. We observed the conformational heterogeneity of LptB2FG and LptB2FGC in micelles and/or proteoliposomes using pulsed dipolar electron spin resonance spectroscopy. Additionally, we monitored LPS binding and release using laser-induced liquid bead ion desorption mass spectrometry. The β-jellyroll domain of LptF stably interacts with the LptG and LptC β-jellyrolls in both the apo and vanadate-trapped states. ATP binding at the cytoplasmic side is allosterically coupled to the selective opening of the periplasmic LptF β-jellyroll domain. In LptB2FG, ATP binding closes the nucleotide binding domains, causing a collapse of the first lateral gate as observed in structures. However, the second lateral gate, which forms the putative entry site for LPS, exhibits a heterogeneous conformation. LptC binding limits the flexibility of this gate to two conformations, likely representing the helix of LptC as either released from or inserted into the transmembrane domains. Our results reveal the regulation of the LPS entry gate through the dynamic behavior of the LptC transmembrane helix, while its β-jellyroll domain is anchored in the periplasm. This, combined with long-range ATP-dependent allosteric gating of the LptF β-jellyroll domain, may ensure efficient and unidirectional transport of LPS across the periplasm.
-
- Biochemistry and Chemical Biology
- Cancer Biology
Many cells in high glucose repress mitochondrial respiration, as observed in the Crabtree and Warburg effects. Our understanding of biochemical constraints for mitochondrial activation is limited. Using a Saccharomyces cerevisiae screen, we identified the conserved deubiquitinase Ubp3 (Usp10), as necessary for mitochondrial repression. Ubp3 mutants have increased mitochondrial activity despite abundant glucose, along with decreased glycolytic enzymes, and a rewired glucose metabolic network with increased trehalose production. Utilizing ∆ubp3 cells, along with orthogonal approaches, we establish that the high glycolytic flux in glucose continuously consumes free Pi. This restricts mitochondrial access to inorganic phosphate (Pi), and prevents mitochondrial activation. Contrastingly, rewired glucose metabolism with enhanced trehalose production and reduced GAPDH (as in ∆ubp3 cells) restores Pi. This collectively results in increased mitochondrial Pi and derepression, while restricting mitochondrial Pi transport prevents activation. We therefore suggest that glycolytic flux-dependent intracellular Pi budgeting is a key constraint for mitochondrial repression.